DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for hypertrophic cardiomyopathy — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypertrophic cardiomyopathy maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypertrophic cardiomyopathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mitogen-activated protein kinase 1 (MAPK1) — MAPK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2~{s}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8AOJ · 1.12 Å · ligand 1-[(2~{S})-2-(5-methyl-3-pyridin-4-yl-1~{H}-pyrazol-4-yl)pyrrolidin-1-yl]propan-1-one (N8L). Experimental structure, not a prediction.
What the evidence adds up to
A 2024 guideline document states that understanding of hypertrophic cardiomyopathy pathogenesis has improved, and new medications addressing molecular mechanisms linked to pathophysiology have been developed. A 2022 review notes that the disease can progress to heart failure and that Chinese and western medicine have their own approaches to treatment, but it does not report any specific trial results or outcome data.
A 1996 review of medical therapy for symptomatic patients states plainly that no therapies have been proven to improve prognosis, and that there are few randomised trials of symptomatic treatment. The major drugs available at that time were beta-blockers, calcium antagonists, and disopyramide. A 2015 article on mechanical aberrations in the disease acknowledges that despite advances in understanding pathogenesis, it remains unclear how flaws in individual sarcomere components produce the observed phenotype.
No abstract reports a controlled trial showing that any drug reduces mortality or improves long-term outcomes in hypertrophic cardiomyopathy. The 2024 guideline mentions new medications but provides no numbers on survival, response rates, or sample sizes. The 1996 review explicitly states the absence of proven prognostic benefit and the scarcity of randomised evidence.
What is still missing are large, randomised controlled trials with hard clinical endpoints, adequate funding for such trials, and a clear stratification of patients by genotype or phenotype to identify who might benefit from any specific molecular therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Arquivos Brasileiros de Cardiologia · 2024 · 24 citations · open access
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024
Abstract1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...]
Frontiers in Physiology · 2015 · 3 citations · open access
Mechanical aberrations in hypetrophic cardiomyopathy: emerging concepts
AbstractHypertrophic cardiomyopathy is the most common monogenic disorder in cardiology. Despite important advances in understanding disease pathogenesis, it is not clear how flaws in individual sarcomere components are responsible for the observed phenotype. The aim of this article is to provide a brief interpretative analysis of some currently proposed pathophysiological mechanisms of hypertrophic cardiomyopathy, with a special emphasis on alterations in the cardiac mechanical properties.
Journal of Contemporary Medical Practice · 2022 · 0 citations · open access
Progress in Clinical Treatment of Hypertrophic Cardiomyopathy with Traditional Chinese and Western Medicine
AbstractHypertrophic cardiomyopathy refers to cardiac hypertrophy caused by hypertension, aortic stenosis and other factors, with dyspnea, precardiac pain, fatigue, palpitations and other clinical manifestations, and ultimately can progress to heart failure; The clinical incidence of this disease is increasing year by year, and the complications are numerous, which seriously affect the prognosis. For the treatment of this disease, Chinese and western medicine have their own opinions, through combing the latest domestic and foreign relevant literature, systematically elaborated in recent years about the progress of Chinese and western medicine treatment of this disease, for the majority of doctors reference.
Medical Therapy for Symptomatic Patients with Hypertrophic Cardiomyopathy
AbstractHypertrophic cardiomyopathy is a relatively uncommon myocardial disease with a heterogeneous presentation and complex pathophysiology. The condition is often asymptomatic; when symptoms are present, however, they are usually multiple, and each has several potential mechanisms. No therapies have been proven to improve prognosis, and there are few randomized trials of symptomatic treatment. Within these limitations, an approach to assessing the symptomatic patient is presented. The major drugs available for symptomatic therapy, namely beta-blockers, calcium antagonists and disopyramide, are reviewed. An overall management plan and a step-by-step strategy for the treatment of the symptomatic patient are presented.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
